Innate Pharma announces $5M upfront payment from Takeda

Under the terms of the license agreement, Innate (IPHA) will receive a $5M upfront payment from Takeda (TAK) and is eligible to receive up to $410M in future development, regulatory and commercial milestones if all milestones are achieved during the term of the agreement, plus royalties on potential net sales of any commercial product resulting from the license.